Supplements
Astaxanthin: carotenoid forms, skin and exercise trials, lipid findings and product-specific safety
On this page
Astaxanthin is a red-orange carotenoid pigment in the xanthophyll family. It occurs in algae and in seafood such as salmon and crustaceans. It is not a vitamin and has no provitamin A activity in humans: unlike beta-carotene, it does not serve as a source of vitamin A. Food exposure, algal preparations and isolated supplements need separate interpretation.[1]
Distinguish the pigment, source and preparation
| Source or form | Relevant distinction | What the distinction does not prove |
|---|---|---|
| Seafood | Astaxanthin in a whole food | Equivalence to a concentrated capsule[1] |
| H. pluvialis oleoresin | An algal extract rich in astaxanthin esters | That every algal product has the same specification[8] |
| Yeast-derived pigment | Often unesterified, with a different main stereoisomer | A superior clinical effect[1] |
| Synthetic pigment | A mixture of three stereoisomers | Clinical equivalence or inferiority from origin alone[1] |
| Algal meal | Processed biomass, distinct from extracted oleoresin | The same concentration or approved food use[9] |
Esters and stereoisomers describe different properties
An ester has fatty-acid groups attached to the pigment; stereoisomers have different spatial arrangements of the molecule. These are separate distinctions. Algal and yeast sources differ in their typical composition, and synthetic astaxanthin is a stereoisomer mixture. Composition is a useful product identifier, but it does not establish a ranking of clinical effectiveness. A label saying “natural” is not a substitute for a human trial of the preparation.[1]
Digestion changes an esterified preparation
EFSA’s 2023 oleoresin assessment describes chiefly monoesters and diesters, with small amounts of free astaxanthin. It expects esters to be broken down before absorption, with the free pigment absorbed. A capsule’s ingredient weight and its astaxanthin content are therefore different label quantities.[8]
Evidence & uncertainty
Selected astaxanthin studies measure blood exposure, exercise performance, UV-induced skin changes and metabolic markers. These are different endpoints. A 2015 meta-analysis found no significant pooled lipid or glucose improvement across seven randomized trials. An encouraging individual trial therefore needs its own population, preparation and outcome boundaries rather than a broad antioxidant-benefit label.[5]
Selected-source overview · Independent review pendingPublished questions
Does astaxanthin provide vitamin A like beta-carotene?
Selected-source overview · Independent review pending. Read the evidence context.
No. Astaxanthin is a carotenoid without provitamin A activity in humans. Membership in the carotenoid family does not make every pigment a vitamin A source.[1]
Evidence behind this answer
- Astaxanthin for the Food Industry
original narrative review · 2021
Selected original publisher-supplied full text on ResearchGate inspected on 2026-10-14 UTC; publisher/PMC alternatives encountered access challenges; no independent systematic appraisal · Published 2021-05-02; Molecules 26(9):2666; carotenoid identity, no provitamin A activity, algal/yeast/synthetic composition
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does an oil formulation with higher absorption prove greater health benefits?
Selected-source overview · Independent review pending. Read the evidence context.
No. The formulation experiment measured single-dose blood exposure. Clinical benefits require outcome trials of the actual preparation, population and health question.[2]
Evidence behind this answer
- Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations
original human pharmacokinetic study · 2003
Original PubMed abstract and bibliographic record inspected on 2026-10-14 UTC; full text not inspected · 2003 Jul;59(3):211–218; single 40 mg dose, open parallel design and formulation-dependent exposure
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can the skin trial establish astaxanthin as a replacement for sunscreen?
Selected-source overview · Independent review pending. Read the evidence context.
No. It tested selected UV-redness and moisture outcomes in a small sample. It did not establish sunscreen equivalence, a validated SPF or skin-cancer prevention.[3]
Evidence behind this answer
- The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People—A Randomized, Double-Blind, Placebo-Controlled Trial
original randomized controlled trial · 2018
Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal · Published 2018-06-25; 23 enrolled/22 per-protocol; MED change versus post-treatment values, moisture, TEWL and appearance ratings
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the 2023 trial clearly improve its primary prediabetes outcome?
Selected-source overview · Independent review pending. Read the evidence context.
No. The primary glucose-disposal comparison was statistically nonsignificant. Exploratory lipid findings should not be mistaken for demonstrated prevention or treatment of diabetes.[4]
Evidence behind this answer
- Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia
original randomized controlled trial · 2023
Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal · First online 2023-03-30; July issue; 36 randomized/34 completed, 24 weeks; primary glucose-disposal null, exploratory lipids, pregnancy-capable exclusion
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Why do favorable cholesterol reports not establish reliable lipid treatment?
Selected-source overview · Independent review pending. Read the evidence context.
The older seven-trial synthesis found no significant pooled lipid improvement. Later individual findings need assessment alongside product differences, small samples and exploratory outcomes.[5]
Evidence behind this answer
- Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials
original systematic review meta analysis · 2015
Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal · 2015 Apr;11(2):253–266; seven RCTs/280 participants, pooled lipids/glucose and triglyceride confidence interval
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
How large was the completed sample in the favorable cycling trial?
Selected-source overview · Independent review pending. Read the evidence context.
Only 14 of 21 randomized cyclists completed, seven per group. That small completion sample limits confidence in applying its time-trial improvement broadly.[6]
Evidence behind this answer
- Effect of astaxanthin on cycling time trial performance
original randomized controlled trial · 2011
Original author-university publication abstract inspected on 2026-10-14 UTC; full text not inspected · 2011;32(11):882–888; 21 randomized/14 completed, 4 mg/day, 28 days and pre-exhaustion time trial
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can blood astaxanthin rise without better endurance performance?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. The 32-person 2013 trial increased plasma astaxanthin but did not improve time-trial performance, fat oxidation or its measured antioxidant markers.[7]
Evidence behind this answer
- Astaxanthin supplementation does not augment fat use or improve endurance performance
original randomized controlled trial · 2013
Original author-university publication abstract inspected on 2026-10-14 UTC; full text not inspected · 2013 Jun;45(6):1158–1165; 32 trained men, 20 mg/day, four weeks; plasma increase with null markers and performance
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the dated EU oleoresin assessment use one supplement amount for every age?
Selected-source overview · Independent review pending. Read the evidence context.
No. It reports age-specific maxima for the specified preparation. These conditions are not universal dosing advice or proof of clinical benefit.[8]
Evidence behind this answer
- Safety of a change in specifications of the novel food oleoresin from Haematococcus pluvialis containing astaxanthin pursuant to Regulation (EU) 2015/2283
agency novel food safety assessment · 2023
Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal · Published 2023-11-08; adopted 2023-09-26; ester forms/absorption, ADI, isomer uncertainty and dated age-specific oleoresin conditions
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is the 2025 algal-meal assessment interchangeable with an oleoresin assessment?
Selected-source overview · Independent review pending. Read the evidence context.
No. It concerns processed biomass and specified new food uses. Product concentration, total exposure and conditions on combining supplements must be retained.[9]
Evidence behind this answer
- Safety of algal meal from Haematococcus pluvialis containing astaxanthin as a novel food pursuant to Regulation (EU) 2015/2283
agency novel food safety assessment · 2025
Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal · Publisher first published 2025-12-03; adopted 2025-09-30; amended 2026-02-18 with an editorial correction not materially affecting contents/outcome; algal meal identity, distinct oleoresin assessment, combined exposure and specified new-food-use conclusion
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
A carrier can change absorption without establishing a treatment
A 2003 open parallel pharmacokinetic study gave healthy men one 40 mg dose in different formulations. Lipid-based preparations produced about 1.7–3.7 times the blood exposure of the reference preparation. This demonstrates a formulation effect for that experiment. It does not identify an optimal daily dose, show better disease outcomes, or prove that every oil-containing retail capsule has the same behavior.[2]
Skin findings depend on the exact UV endpoint
A 2018 randomized trial enrolled 23 adults and analyzed 22 per protocol after 4 mg/day or placebo for nine weeks. Change in the minimal erythema dose, a UV-redness threshold, favored astaxanthin; the raw post-treatment thresholds did not differ significantly (P=.162). Moisture findings depended on UV intensity, and transepidermal water loss did not differ. Several appearance ratings were also null. The small, mainly female study had manufacturer-employed investigators. It did not establish a validated SPF, sunscreen equivalence or prevention of skin cancer; those were not its tested outcomes.[3]
A later metabolic trial had a null primary endpoint
A 2023 trial randomized 36 adults with prediabetes and dyslipidaemia; 34 completed 12 mg/day or placebo over 24 weeks. The primary glucose-disposal outcome was not statistically significant (P=.078). LDL and total cholesterol declined from baseline in the astaxanthin group, while triglycerides, fasting glucose, HbA1c and oral glucose-tolerance measures did not improve. Lipid and biomarker analyses were exploratory, without adjustment for multiple comparisons. The title’s cholesterol claim should be read alongside the primary result. The trial did not measure reduced cardiovascular events.[4]
Older pooled evidence did not establish lipid treatment
The 2015 review pooled seven randomized trials totaling 280 participants. It found no statistically significant overall changes in total cholesterol, LDL, HDL, triglycerides or glucose. For triglycerides, the pooled difference was −4.76 mg/dL, with a 95% confidence interval from −21.52 to +12.00 mg/dL. That interval includes favorable and unfavorable values. This older synthesis does not include every later trial; it provides a concrete counterweight to selecting only positive results and cannot establish reliable treatment of dyslipidaemia.[5]
One small cycling experiment was favorable
A 2011 study randomized 21 competitive cyclists, but only 14 completed, seven per group. They took 4 mg/day or placebo for 28 days. After a two-hour pre-exhaustion ride, average improvement in a 20 km time trial was 121 seconds with astaxanthin and 19 seconds with placebo. A small completion sample and substantial dropout constrain the result. This specific test cannot establish a general improvement in endurance, muscle recovery or everyday energy in other populations.[6]
A higher-dose experiment did not reproduce a performance benefit
In 2013, 32 well-trained young male cyclists or triathletes took 20 mg/day or placebo for four weeks. Plasma astaxanthin increased, yet measured antioxidant capacity, malondialdehyde, fat oxidation and time-trial performance did not improve. The contrast with the smaller favorable experiment does not show that one particular dose always works or fails: protocols and samples differed. It does show why absorption or an antioxidant mechanism cannot be assumed to improve athletic performance.[7]
A safety assessment is specific to exposure and product
EFSA’s 2023 assessment retained an acceptable daily intake of 0.2 mg/kg body weight. It described oleoresin supplement limits of 2.3 mg/day for ages 3 to under 10, 5.7 mg/day for ages 10 to under 14, and 8 mg/day for people older than 14. These are dated, product-specific EU conditions, not a personal regimen or evidence of benefit. The panel also noted that toxicity of individual isomers had not been studied separately.[8]
New food uses add another exposure source
EFSA’s December 2025 opinion assessed algal meal containing about 5% astaxanthin, separately from oleoresin. It concluded that proposed new uses in dairy alternatives and fruit juices were safe under the assessed conditions, provided children and adolescents did not also consume astaxanthin supplements that day. Combining food fortification and supplements can change total exposure. The opinion’s product specifications and use conditions should not be generalized to every pigment source or concentration. A regulatory safety conclusion for a food use also does not establish effectiveness against a medical condition.[9]
A monitored adult trial cannot settle pregnancy safety
The 2023 metabolic trial reported no treatment-related adverse events, but excluded people capable of becoming pregnant. It cannot establish safety during pregnancy or breastfeeding, or uncommon harms beyond its limited sample and follow-up. Research amounts describe supervised experiments; they are not personal supplement recommendations.[4]
References
- Astaxanthin for the Food Industry
Original narrative review
Stachowiak and Szulc · Content/publication date: 2021
Accessed: 2026-10-14 UTC · Selected original publisher-supplied full text on ResearchGate inspected on 2026-10-14 UTC; publisher/PMC alternatives encountered access challenges; no independent systematic appraisal
Cited sections: Published 2021-05-02; Molecules 26(9):2666; carotenoid identity, no provitamin A activity, algal/yeast/synthetic compositionUsed for identity and composition, not its broad health-benefit language or superseded regulatory statements.
- Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations
Original human pharmacokinetic study
Odeberg and colleagues · Content/publication date: 2003
Accessed: 2026-10-14 UTC · Original PubMed abstract and bibliographic record inspected on 2026-10-14 UTC; full text not inspected
Cited sections: 2003 Jul;59(3):211–218; single 40 mg dose, open parallel design and formulation-dependent exposure - The Protective Role of Astaxanthin for UV-Induced Skin Deterioration in Healthy People—A Randomized, Double-Blind, Placebo-Controlled Trial
Original randomized controlled trial
Ito and colleagues · Content/publication date: 2018
Accessed: 2026-10-14 UTC · Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal
Cited sections: Published 2018-06-25; 23 enrolled/22 per-protocol; MED change versus post-treatment values, moisture, TEWL and appearance ratingsSmall, mainly female sample; investigators employed by Fujifilm; no validated SPF or cancer-prevention outcome.
- Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia
Original randomized controlled trial
Ciaraldi and colleagues · Content/publication date: 2023
Accessed: 2026-10-14 UTC · Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal
Cited sections: First online 2023-03-30; July issue; 36 randomized/34 completed, 24 weeks; primary glucose-disposal null, exploratory lipids, pregnancy-capable exclusionSecondary/exploratory comparisons were not adjusted for multiplicity; baseline lipid changes are not clinical-event evidence.
- Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials
Original systematic review meta analysis
Ursoniu and colleagues · Content/publication date: 2015
Accessed: 2026-10-14 UTC · Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal
Cited sections: 2015 Apr;11(2):253–266; seven RCTs/280 participants, pooled lipids/glucose and triglyceride confidence intervalA dated synthesis that predates the 2023 metabolic trial; not claimed to represent all current trials.
- Effect of astaxanthin on cycling time trial performance
Original randomized controlled trial
Earnest and colleagues · Content/publication date: 2011
Accessed: 2026-10-14 UTC · Original author-university publication abstract inspected on 2026-10-14 UTC; full text not inspected
Cited sections: 2011;32(11):882–888; 21 randomized/14 completed, 4 mg/day, 28 days and pre-exhaustion time trial - Astaxanthin supplementation does not augment fat use or improve endurance performance
Original randomized controlled trial
Res and colleagues · Content/publication date: 2013
Accessed: 2026-10-14 UTC · Original author-university publication abstract inspected on 2026-10-14 UTC; full text not inspected
Cited sections: 2013 Jun;45(6):1158–1165; 32 trained men, 20 mg/day, four weeks; plasma increase with null markers and performance - Safety of a change in specifications of the novel food oleoresin from Haematococcus pluvialis containing astaxanthin pursuant to Regulation (EU) 2015/2283
Agency novel food safety assessment
EFSA NDA Panel · Content/publication date: 2023
Accessed: 2026-10-14 UTC · Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal
Cited sections: Published 2023-11-08; adopted 2023-09-26; ester forms/absorption, ADI, isomer uncertainty and dated age-specific oleoresin conditionsSpecification and exposure safety, not clinical efficacy or a personal dose recommendation.
- Safety of algal meal from Haematococcus pluvialis containing astaxanthin as a novel food pursuant to Regulation (EU) 2015/2283
Agency novel food safety assessment
EFSA NDA Panel · Content/publication date: 2025
Accessed: 2026-10-14 UTC · Selected original full-text definition, methods, results or discussion passages inspected on 2026-10-14 UTC; no independent systematic appraisal
Cited sections: Publisher first published 2025-12-03; adopted 2025-09-30; amended 2026-02-18 with an editorial correction not materially affecting contents/outcome; algal meal identity, distinct oleoresin assessment, combined exposure and specified new-food-use conclusionPublisher HTML says December issue/first publication December 3; some indexed PDF bibliographies say November. Actual first-publication date retained from inspected publisher metadata. The 2026-02-18 amendment corrects an author name and proprietary-data sections without materially affecting the contents or outcome.
Scope & review
- Population
- Source-specific adult research participants; evidence does not establish use in pregnancy, breastfeeding or children
- Exposure or intervention
- Seafood astaxanthin, algal esters/oleoresin/meal, yeast/synthetic composition and source-specific oral formulations
- Comparison
- Each trial retains its own placebo or alternative formulation; foods, isolated supplements and proprietary extracts are not interchangeable
- Outcomes
- Absorption, UV-redness/moisture outcomes, metabolic biomarkers, cycling performance and product-specific exposure safety
- Timeframe
- Selected short-term trials and dated reviews; follow-up and product are retained for each study
- Jurisdiction
- International human research and specifically dated agency assessments; product authorization and labeling are jurisdiction-specific
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-14 UTC: Added a bounded supplement explanation; independent qualified review remains pending.
What this article still leaves open
- Do larger independent trials demonstrate patient-important skin or metabolic benefits?
- Which formulations reproduce outcome benefits rather than only increasing blood exposure?
- What are long-term interaction and pregnancy/breastfeeding safety profiles?
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.